Neurofilament light predicts neurological outcome after subarachnoid haemorrhage.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
12 04 2021
Historique:
received: 16 06 2020
revised: 08 09 2020
accepted: 11 10 2020
pubmed: 1 2 2021
medline: 14 8 2021
entrez: 31 1 2021
Statut: ppublish

Résumé

To improve outcome prediction following subarachnoid haemorrhage (SAH), we sought a biomarker integrating early brain injury and multiple secondary pathological processes in a prospective study of 42 non-traumatic SAH patients and 19 control individuals. Neurofilament light (NF-L) was elevated in CSF and serum following SAH. CSF and serum NF-L on Days 1-3 post-SAH strongly predicted modified Rankin score at 6 months, independent of World Federation of Neurosurgical Societies (WFNS) score. NF-L from Day 4 onwards also had a profound impact on outcome. To link NF-L to a SAH-specific pathological process, we investigated NF-L's relationship with extracellular haemoglobin. Most CSF haemoglobin was not complexed with haptoglobin, yet was able to be bound by exogenous haptoglobin i.e. haemoglobin was scavengeable. CSF scavengeable haemoglobin was strongly predictive of subsequent CSF NF-L. Next, we investigated NF-L efflux from the brain after SAH. Serum and CSF NF-L correlated positively. The serum/CSF NF-L ratio was lower in SAH versus control subjects, in keeping with glymphatic efflux dysfunction after SAH. CSF/serum albumin ratio was increased following SAH versus controls. The serum/CSF NF-L ratio correlated negatively with the CSF/serum albumin ratio, indicating that transfer of the two proteins across the blood-brain interface is dissociated. In summary, NF-L is a strong predictive marker for SAH clinical outcome, adding value to the WFNS score, and is a promising surrogate end point in clinical trials.

Identifiants

pubmed: 33517369
pii: 6124756
doi: 10.1093/brain/awaa451
pmc: PMC8041040
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0
neurofilament protein L 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

761-768

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

JAMA Neurol. 2019 Feb 1;76(2):187-193
pubmed: 30419087
J Neurochem. 2012 Jun;121(5):785-92
pubmed: 22380637
Brain Commun. 2020 Jan 3;2(1):fcz053
pubmed: 32346673
Acta Neurochir Suppl. 2015;120:51-4
pubmed: 25366599
Curr Opin Neurobiol. 2020 Apr;61:29-39
pubmed: 31838254
Neurosci Lett. 2006 Aug 14;404(1-2):132-6
pubmed: 16806706
Exp Neurobiol. 2019 Feb;28(1):104-118
pubmed: 30853828
J Neurotrauma. 2005 Mar;22(3):407-14
pubmed: 15785235
BMJ. 2018 Jan 18;360:j5745
pubmed: 29348138
J Neurol Neurosurg Psychiatry. 1988 Nov;51(11):1457
pubmed: 3236024
Stroke. 2009 Oct;40(10):3393-5
pubmed: 19679846
Neurosurgery. 1980 Jan;6(1):1-9
pubmed: 7354892
Acta Neurol Scand. 2018 Feb;137(2):199-203
pubmed: 29164612
J Cereb Blood Flow Metab. 2008 Jun;28(6):1261-71
pubmed: 18319731
Nat Rev Neurol. 2014 Jan;10(1):44-58
pubmed: 24323051
J Neurol Sci. 1978 Jul;37(3):205-14
pubmed: 681976
Neurosci Biobehav Rev. 2018 Jul;90:26-33
pubmed: 29608988
Transl Stroke Res. 2020 Aug;11(4):671-677
pubmed: 31808039
Neurology. 2013 Apr 9;80(15):1385-92
pubmed: 23486875
Stroke. 2017 Nov;48(11):2958-2963
pubmed: 28974630
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):753-9
pubmed: 16705199
Lancet Neurol. 2018 Nov;17(11):1016-1024
pubmed: 30353860
Nat Rev Neurol. 2018 Jul;14(7):416-432
pubmed: 29925923
Brain Res. 2007 Apr 20;1142:237-46
pubmed: 17303089
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):157-9
pubmed: 20571038
Scand J Clin Lab Invest. 1977 Sep;37(5):385-90
pubmed: 337459
Acta Neurochir (Wien). 1985;77(3-4):110-32
pubmed: 4072781
Artif Cells Blood Substit Immobil Biotechnol. 1998 Jan;26(1):17-26
pubmed: 9507753

Auteurs

Patrick Garland (P)

Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Matt Morton (M)

Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Ardalan Zolnourian (A)

Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Andrew Durnford (A)

Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Ben Gaastra (B)

Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Jamie Toombs (J)

UK Dementia Research Institute, University College London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.

Amanda J Heslegrave (AJ)

UK Dementia Research Institute, University College London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.

John More (J)

R&D, Bio Products Laboratory Limited, Elstree, Hertfordshire, UK.

Henrik Zetterberg (H)

UK Dementia Research Institute, University College London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Diederik O Bulters (DO)

Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Ian Galea (I)

Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH